Overview

Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

Status:
Completed

Trial end date:
2006-09-01

Target enrollment:

Participant gender:

Summary

This open label study is designed to assess long term glucose control, as measured by hemoglobin A1c (HbA1c) and to evaluate long term safety and tolerability in subjects with type 2 diabetes mellitus who receive subcutaneously injected exenatide administered twice a day.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Exenatide